Appointment of David Quigley to CervoMed Inc. Board of Directors

On October 27, 2025, CervoMed Inc. appointed David Quigley to its Board of Directors. Mr. Quigley, a former Senior Partner at McKinsey & Company, brings extensive experience in life sciences and private equity. His appointment is part of CervoMed's strategic efforts as it prepares for Phase 3 trials and commercialization planning for its lead drug candidate, neflamapimod, aimed at treating dementia with Lewy bodies (DLB). Mr. Quigley was granted a stock option to purchase 16,200 shares of the company's common stock, with an exercise price of $7.02, vesting over 36 months. The Board size was expanded from seven to eight members to accommodate his appointment.